BIOMARKER:

EGFR mutation + TP53 mutation

B | Sensitive

C3 | Sensitive

B | Resistant

C3 | Resistant

Non Small Cell Lung Cancer

Pancreatic Cancer

Lung Adenocarcinoma

Lung Cancer

bevacizumab + aumolertinib

EGFR mutation + TP53 mutation|Non Small Cell Lung Cancer|bevacizumab + aumolertinib

aumolertinib

EGFR mutation + TP53 mutation|Non Small Cell Lung Cancer|aumolertinib

osimertinib

EGFR mutation + TP53 mutation|Non Small Cell Lung Cancer|osimertinib

EGFR mutation + TP53 mutation|Lung Cancer|osimertinib

PD1 inhibitor

EGFR mutation + TP53 mutation|Pancreatic Cancer|PD1 inhibitor

EGFR inhibitor

EGFR mutation + TP53 mutation|Non Small Cell Lung Cancer|EGFR inhibitor

EGFR mutation + TP53 mutation|Lung Adenocarcinoma|EGFR inhibitor

Tyrosine kinase inhibitor

EGFR mutation + TP53 mutation|Non Small Cell Lung Cancer|Tyrosine kinase inhibitor

EGFR mutation + TP53 mutation|Lung Adenocarcinoma|Tyrosine kinase inhibitor

Immunotherapy

EGFR mutation + TP53 mutation|Non Small Cell Lung Cancer|Immunotherapy

EGFR inhibitor + Angiogenesis inhibitor

EGFR mutation + TP53 mutation|Non Small Cell Lung Cancer|EGFR inhibitor + Angiogenesis inhibitor